Microglia

Microglia are specialized immune cells (macrophage lineage) that reside in the central nervous system (CNS), where they play key roles in maintaining tissue homeostasis, responding to injury or infection, clearing cellular debris by phagocytosis, remodeling synapses, and modulating inflammation and neuroprotection[2][3][4][5]. Microglia activation refers to the transition of these cells from a surveillant "resting" phenotype to an activated state in response to cues such as pathogens (via PAMPs), injury (via DAMPs), cytokines, or toxic protein aggregates[1][3][4][7]. Activated microglia can adopt a spectrum of functional phenotypes—ranging from pro-inflammatory (historically termed "M1") to anti-inflammatory and reparative ("M2") states—which influence their cytokine, chemokine, and trophic factor secretion profiles[1][2][3][7]. This process is critically involved in the pathogenesis of neurodegenerative diseases, neuroinflammation, CNS infection, and traumatic brain injury by modulating both protective (clearance, repair) and potentially damaging (inflammation-driven neurotoxicity) responses[3][4][6][7][9]. Microglia activation involves cell surface and intracellular receptors, including toll-like receptors (TLRs, especially TLR4), CSF1R, and cytokine receptors among others[1][3][9]. There are currently no drugs that directly and selectively "target microglia activation" as a molecular entity; therapeutic interventions generally aim to modulate microglial functions or signaling pathways. Note: "Microglia activation" is not a molecular or protein target but a cellular functional state/process. No single molecule or receptor corresponds to this entity, making it an incorrect term for a canonical drug target[1][2][3][4][5][6][7][9].

Other names

Microglial activationactivated microgliamicroglial polarizationCNS macrophages

Inhibition of pro-inflammatory signaling pathways (e.g., NF-κB, MAPK) Inhibition or modulation of colony stimulating factor 1 receptor (CSF1R) signaling Modulation of cytokine production and release Blockade of toll-like receptor (TLR) activation (e.g., TLR4 antagonism)